Skip to main content
Fig. 2 | Microbial Cell Factories

Fig. 2

From: Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment

Fig. 2

Diagram of antibodies and their respective fragments, from sources such as human, mouse, genetically humanized mouse, and alpaca. a mAb general view fragment antigen-binding region composed of two heavy and two light chains, disposed in Fab fragment and the fragment crystallizable (Fc) which consists of constant heavy chains (CH2 and CH3). The variable region formed by two arms which bind to antigen through complementary determining regions (CDRs). b Fab fragment is formed by the light chain (VL and CL) and by the heavy chain’s variable (VH) region and a portion of its constant (CH1). c A single-chain variable fragment (scFv) comprises the fusion of the VH and VL of immunoglobulins, connected by a linker peptide. d Single domain antibody (nanobody) consists of a monomeric variable domain (VH) of a heavy-chain antibody of a common IgG. e Antibodies from Camelidae or heavy-chain antibodies, presenting a variable region of a heavy chain (VHH) and do not present light chains. f The VHH (Nanobody) derived from heavy-chain only antibodies have a longer CDR3 loop compared to VH-VL domains in mAbs

Back to article page